174 related articles for article (PubMed ID: 21460378)
1. 2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial.
Bachner M; Loriot Y; Gross-Goupil M; Zucali PA; Horwich A; Germa-Lluch JR; Kollmannsberger C; Stoiber F; Fléchon A; Oechsle K; Gillessen S; Oldenburg J; Cohn-Cedermark G; Daugaard G; Morelli F; Sella A; Harland S; Kerst M; Gampe J; Dittrich C; Fizazi K; De Santis M
Ann Oncol; 2012 Jan; 23(1):59-64. PubMed ID: 21460378
[TBL] [Abstract][Full Text] [Related]
2. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.
De Santis M; Becherer A; Bokemeyer C; Stoiber F; Oechsle K; Sellner F; Lang A; Kletter K; Dohmen BM; Dittrich C; Pont J
J Clin Oncol; 2004 Mar; 22(6):1034-9. PubMed ID: 15020605
[TBL] [Abstract][Full Text] [Related]
3. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
De Santis M; Bokemeyer C; Becherer A; Stoiber F; Oechsle K; Kletter K; Dohmen BM; Dittrich C; Pont J
J Clin Oncol; 2001 Sep; 19(17):3740-4. PubMed ID: 11533096
[TBL] [Abstract][Full Text] [Related]
4. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
Decoene J; Winter C; Albers P
Urol Oncol; 2015 Jan; 33(1):23.e15-23.e21. PubMed ID: 25454484
[TBL] [Abstract][Full Text] [Related]
5. Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up.
Conduit C; Koh TT; Hofman MS; Toner GC; Goad J; Lawrentschuk N; Tai KH; Lewin JH; Tran B
Cancer Imaging; 2022 Oct; 22(1):58. PubMed ID: 36209121
[TBL] [Abstract][Full Text] [Related]
6. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
Becherer A; De Santis M; Karanikas G; Szabó M; Bokemeyer C; Dohmen BM; Pont J; Dudczak R; Dittrich C; Kletter K
Eur J Radiol; 2005 May; 54(2):284-8. PubMed ID: 15837411
[TBL] [Abstract][Full Text] [Related]
7. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma.
Hinz S; Schrader M; Kempkensteffen C; Bares R; Brenner W; Krege S; Franzius C; Kliesch S; Heicappel R; Miller K; de Wit M
J Urol; 2008 Mar; 179(3):936-40; discussion 940. PubMed ID: 18207171
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis.
Treglia G; Sadeghi R; Annunziata S; Caldarella C; Bertagna F; Giovanella L
Biomed Res Int; 2014; 2014():852681. PubMed ID: 24963486
[TBL] [Abstract][Full Text] [Related]
9. [Assessment of residual tumours after systemic treatment of metastatic seminoma: ¹⁸F-2-fluoro-2-deoxy-D-glucose positron emission tomography - meta-analysis of diagnostic value].
Müller J; Schrader AJ; Jentzmik F; Schrader M
Urologe A; 2011 Mar; 50(3):322-7. PubMed ID: 21161157
[TBL] [Abstract][Full Text] [Related]
10. Can we rely on PET in the follow-up of advanced seminoma patients?
Siekiera J; Małkowski B; Jóźwicki W; Jasiński M; Wronczewski A; Pietrzak T; Chmielowska E; Petrus A; Kamecki K; Mikołajczak W; Kraśnicki K; Chłosta P; Drewa T
Urol Int; 2012; 88(4):405-9. PubMed ID: 22507953
[TBL] [Abstract][Full Text] [Related]
11. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Harper PG; Huddart RA
Br J Cancer; 2000 Oct; 83(7):863-9. PubMed ID: 10970686
[TBL] [Abstract][Full Text] [Related]
12. The role of 18F-FDG PET/CT in the management of testicular cancers.
Cook GJ; Sohaib A; Huddart RA; Dearnaley DP; Horwich A; Chua S
Nucl Med Commun; 2015 Jul; 36(7):702-8. PubMed ID: 25757201
[TBL] [Abstract][Full Text] [Related]
13. The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Loriot Y; Texier M; Culine S; Fléchon A; Thiery-Vuillemin A; Gravis G; Geoffrois L; Chevreau C; Gross-Goupil M; Barthelemy P; Bompas E; Mahammedi H; Laguerre B; Lacourtoisie SA; Helissey C; Ladoire S; Abraham C; Massard C; Grimaldi S; Fizazi K
Eur Urol; 2022 Aug; 82(2):172-179. PubMed ID: 35599187
[TBL] [Abstract][Full Text] [Related]
14. Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up.
Karapetis CS; Strickland AH; Yip D; Steer C; Harper PG
Intern Med J; 2003; 33(9-10):427-35. PubMed ID: 14511195
[TBL] [Abstract][Full Text] [Related]
15. Tumor markers and
Dondi F; Albano D; Bertagna F; Giubbini R
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(5):287-292. PubMed ID: 34425969
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy for Post-Chemotherapy Residual Mass in Advanced Seminoma: A Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Risk-adapted Approach.
Murthy V; Karmakar S; Carlton J; Joshi A; Krishnatry R; Prabhash K; Noronha V; Bakshi G; Prakash G; Pal M; Menon S; Agrawal A; Rangarajan V
Clin Oncol (R Coll Radiol); 2021 Jul; 33(7):e315-e321. PubMed ID: 33608206
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET/CT impact on testicular tumours clinical management.
Ambrosini V; Zucchini G; Nicolini S; Berselli A; Nanni C; Allegri V; Martoni A; Rubello D; Cricca A; Fanti S
Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):668-73. PubMed ID: 24265073
[TBL] [Abstract][Full Text] [Related]
18.
Petrović J; Beatović S; Šobić-Šaranović D; Odalović S; Stojiljković M; Grozdic-Milojevic I; Veljkovic M; Jovanovic D; Artiko V
Hell J Nucl Med; 2022; 25(1):19-25. PubMed ID: 35388800
[TBL] [Abstract][Full Text] [Related]
19. [Positron emission tomography in germ cell tumors in men : Possibilities and limitations].
Schriefer P; Hartmann M; Oechsle K; Meyer CP; Klutmann S; Fisch M; Bokemeyer C; Oing C
Urologe A; 2019 Apr; 58(4):418-423. PubMed ID: 30374517
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors.
Tsatalpas P; Beuthien-Baumann B; Kropp J; Manseck A; Tiepolt C; Hakenberg OW; Burchert W; Franke WG; Wirth MP
Urol Int; 2002; 68(3):157-63. PubMed ID: 11919460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
